Arvind Srivastava, Ph.D.

Arvind Srivastava, Ph.D. Email and Phone Number

SVP, CMC @ Third Arc Bio
New York, NY, US
Arvind Srivastava, Ph.D.'s Location
New York City Metropolitan Area, United States, United States
Arvind Srivastava, Ph.D.'s Contact Details

Arvind Srivastava, Ph.D. personal email

n/a
About Arvind Srivastava, Ph.D.

I am a strategic leader with a proven track record in developing monoclonal antibodies, antibody-drug conjugates, multi-specific antibodies, peptides, and gene therapy products from early-phase development through commercial registration. Throughout my career, I have launched 5 biologics, filed 20+ INDs, and oversaw pharmaceutical operations including cell line development, cell culture, purification, formulation and fill / finish, drug-device, and analytical development. I employ phase-appropriate strategies for efficient development processes, scale-up, tech transfer, analytical characterization, stability, and process validation. My peers know me as skilled in collaborating with cross-functional teams, industry thought leaders, and in implementing industry-leading practices that drive efficiency in biologics development and manufacturing. I am recognized as an expert in global regulations, BLA, IND, pre-approval inspections and global audits, and in influencing the scientific community through publications and presentations.

Arvind Srivastava, Ph.D.'s Current Company Details
Third Arc Bio

Third Arc Bio

View
SVP, CMC
New York, NY, US
Website:
thirdarcbio.com
Employees:
33
Arvind Srivastava, Ph.D. Work Experience Details
  • Third Arc Bio
    Svp, Cmc
    Third Arc Bio
    New York, Ny, Us
  • Third Arc Bio
    Senior Vice President, Cmc
    Third Arc Bio Aug 2024 - Present
    Philadelphia, Pennsylvania, Us
    Third Arc Bio is dedicated to developing multifunctional antibodies that precisely activate or inhibit T cells at a tissue-specific level. This approach aims to achieve superior efficacy and safety for solid tumors and immune and inflammatory diseases.
  • Probio Development Partners
    Cmc Consultant
    Probio Development Partners Apr 2024 - Present
    Provide comprehensive end-to-end CMC consultancy to biotech companies, pharmaceutical firms, and compounding pharmacies, supporting the development of life-saving small molecules, proteins/peptides, and biologics.
  • Avantor
    Technical Fellow / Vice President, Research & Development
    Avantor 2018 - Apr 2024
    Radnor Township, Pennsylvania, Us
    Led Contract Development and Manufacturing Organization (CDMO) with 20+ senor level professionals, overseeing operations across cell line development, cell culture, purification, analytical, formulation and fill / finish. Managed and forecasted resources effectively. Conducted technology assessments, identified operational challenges, and implemented innovative technical solutions to enhance manufacturing efficiency. Authored and reviewed technical reports and whitepapers to support clients in regulatory submissions.Selected accomplishments:• Cultivated engaging and collaborative work culture, improving employee survey results from mid-60s to over 90%.• Established antibody and gene therapy platforms and optimized efficient workflow solutions by building infrastructure and hiring 20+ skilled professionals.• Oversaw development of purification process for highly sensitive multi-specific antibody, boosting yield by 30%+ and transferring technology to the client.• Led team in formulating high-concentration products with proprietary excipients, achieving 90% reduction in viscosity and enhancing product stability.• Developed proprietary technology that improved AAV manufacturing yield by 30%.
  • Eli Lilly And Company
    Research Advisor, Drug Product Development
    Eli Lilly And Company 2016 - 2017
    Indianapolis, Indiana, Us
    Led team of 15, including director and senior scientists developing biologics from early-phase to late-phase, including post-market changes. Served as primary liaison between CMC team and management, accountable for technical success of bispecific projects. Offered strategic guidance on developability assessments for new products in collaboration with research team. Played pivotal role in driving continuous process improvement and developing life-cycle management strategies.Selected accomplishments:• Reduced first human dose (FHD) timelines by 6 months for bispecific through innovative development strategies.• Partnered with cell culture, purification, and analytical teams to design streamlined purification process for bispecific product, consolidating 3-unit operations into 2 and reducing production costs by 20%.
  • Eli Lilly And Company
    Director, Formulation Development
    Eli Lilly And Company 2009 - 2016
    Indianapolis, Indiana, Us
    Led team of 12, including managers and senior scientist level professionals overseeing drug product development and manufacturing process development, drug-device development from early development stages through regulatory submissions, focused on creating efficient processes and control strategies for clinical and commercial drug products. Actively participated in governance and portfolio reviews to provide guidance on continuous improvement and organizational strategy.Selected accomplishments:• Led formulation and process development, tech transfer, and process validation for 4 commercial drug products, authored BLA, and supported global pre-approval inspections and GMP audits.• Developed risked-base formulation and process for 15+ biologics and authored IND, enabling FHD in less than 12 months.• Designed creative bridging study between historical and new analytical methods in partnership with analytical team, achieving 36-month commercial shelf-life for Cyramza based on 6 months of primary stability data.• Established risk-based, phase-appropriate comparability study designs for API and drug product, leading to 30% reduction in analytical tests by eliminating non-stability-indicating assays.
  • Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company
    Associate Director, Formulation Development
    Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company 2007 - 2009
    Us
    Promoted to establish internal capabilities for phase-appropriate formulation development of biologics from early phase through commercial registration. Led design, execution and delivery of formulation and process development studies for liquid and lyophilized products.
  • Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company
    Senior Manager, Formulation Development
    Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company 2006 - 2007
    Us
    Led formulation development of new drug candidates on a timely manner and communicated formulation decisions to senior management. Supervised and reviewed performance of a group of formulation scientists and analysis.
  • Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company
    Senior Scientist, Formulation Development
    Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company 2005 - 2006
    Us
    Senior Scientist, Formulation (2005-2005)Led a team responsible for developing formulation, analytical methods and characterization for biologics drug products. Enhanced the analytical capability and brought high throughput concept into the formulation screening.
  • Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company
    Scientist, Formulation Development
    Imclone Systems, A Wholly-Owned Subsidiary Of Eli Lilly And Company 2003 - 2005
    Us
    Scientist III, Formulation (2003-2004)Led formulation development and developed stability indicating methods. Provided guidance to junior colleagues.

Arvind Srivastava, Ph.D. Skills

Biotechnology 21 Cfr Part 11 Antibodies Biochemistry Biopharmaceuticals Cancer Cell Cell Biology Cell Culture Chromatography Clinical Development Drug Development Data Analysis Drug Discovery Formulation Glp Gmp Hplc Genomics Immunology Laboratory Lifesciences Monoclonal Antibodies Pcr Pharmaceutical Industry Protein Chemistry R&d Oncology Statistics Sop Strategy Validation Toxicology Technology Transfer Vaccines Molecular Biology Fda Regulatory Affairs Life Sciences Good Laboratory Practice High Performance Liquid Chromatography

Arvind Srivastava, Ph.D. Education Details

  • University Of North Carolina At Chapel Hill
    University Of North Carolina At Chapel Hill
    Biochemistry
  • Tata Institute Of Fundamental Research, Mumbai
    Tata Institute Of Fundamental Research, Mumbai
    Chemistry
  • Banaras Hindu University
    Banaras Hindu University
    Chemistry

Frequently Asked Questions about Arvind Srivastava, Ph.D.

What company does Arvind Srivastava, Ph.D. work for?

Arvind Srivastava, Ph.D. works for Third Arc Bio

What is Arvind Srivastava, Ph.D.'s role at the current company?

Arvind Srivastava, Ph.D.'s current role is SVP, CMC.

What is Arvind Srivastava, Ph.D.'s email address?

Arvind Srivastava, Ph.D.'s email address is ar****@****inc.com

What schools did Arvind Srivastava, Ph.D. attend?

Arvind Srivastava, Ph.D. attended University Of North Carolina At Chapel Hill, Tata Institute Of Fundamental Research, Mumbai, Banaras Hindu University.

What skills is Arvind Srivastava, Ph.D. known for?

Arvind Srivastava, Ph.D. has skills like Biotechnology, 21 Cfr Part 11, Antibodies, Biochemistry, Biopharmaceuticals, Cancer, Cell, Cell Biology, Cell Culture, Chromatography, Clinical Development, Drug Development.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.